Oncology & Cancer

Transfusion dose density affects myelodysplastic syndrome survival

(HealthDay)—Transfusion dose density is an independent prognostic factor for progression-free survival (PFS) in patients with myelodysplastic syndromes treated with red blood cell transfusions (RBCTs), according to a study ...

Oncology & Cancer

Cumbersome blood cancer treatment can be postponed

It's possible to postpone the introduction of blood transfusions for an average of 17 months for patients with the low-risk variant of MDS blood cancer, provided they are given erythropoiesis-stimulating agents (ESA), which ...

page 2 from 2